CLINICAL RESEARCH: ANTIPLATELET THERAPY
The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel
Kevin P. Bliden, BS*,
Joseph DiChiara, BS*,
Lookman Lawal, MD*,
Anand Singla, MD*,
Mark J. Antonino, BS*,
Brian A. Baker, PharmD ,
William L. Bailey, PharmD,
Udaya S. Tantry, PhD* and
Paul A. Gurbel, MD, FACC*,*
* Sinai Center for Thrombosis Research, Baltimore, Maryland
Medical Affairs Department, Daiichi Sankyo, Inc., Parsippany, New Jersey.
Manuscript received January 3, 2008;
revised manuscript received April 18, 2008,
accepted April 30, 2008.
* Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Shapiro Building, Room 209, 2401 West Belvedere Avenue, Baltimore, Maryland 21215. (Email: pgurbel{at}lifebridgehealth.org).
Objectives: The purpose of this study was to examine the effect of cigarette smoking on the platelet response to clopidogrel.
Background: Response variability to clopidogrel therapy has been demonstrated. Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2. Cigarette smoking induces CYP1A2 and may, therefore, enhance the conversion of clopidogrel to its active metabolite.
Methods: Among 259 consecutive patients undergoing elective coronary stenting; 120 were on chronic clopidogrel therapy and were not loaded; and 139 were clopidogrel naïve and were loaded with 600 mg. There were 104 current smokers (CS) and 155 nonsmokers (NS). The adenosine diphosphate (ADP)-stimulated platelet aggregation (PA) was assessed by conventional aggregometry. The ADP-stimulated total and active glycoprotein (GP) IIb/IIIa expression were assessed with flow cytometry. Low PA was defined as the lowest quartile of 5 µmol/l ADP-induced post-treatment PA.
Results: Current smokers on chronic clopidogrel therapy displayed significantly lower PA and ADP-stimulated active GP IIb/IIIa expression compared with NS (p  0.0008 for both). Similarly, CS treated with 600 mg of clopidogrel displayed greater platelet inhibition and lower active GP IIb/IIIa expression compared with NS (p 0.05). In a multivariate Cox regression analysis, current smoking was an independent predictor of low PA (p = 0.0001).
Conclusion: Clopidogrel therapy in CS is associated with increased platelet inhibition and lower aggregation as compared with NS. The mechanism of the smoking effect deserves further study and may be an important cause of response variability to clopidogrel therapy.
Key Words: clopidogrel • platelets • smoking • stenting
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | CS = current smokers | | CYP = consecutive cytochrome P450 | | GP = glycoprotein | | IPA = inhibition of platelet aggregation | | MPA = maximum platelet aggregation | | NS = nonsmokers | | PCI = percutaneous coronary intervention |
|
This article has been cited by other articles:
|
|
|
|
 
D. Sibbing, W. Koch, S. Massberg, R. A. Byrne, J. Mehilli, S. Schulz, K. Mayer, I. Bernlochner, A. Schomig, and A. Kastrati
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
Eur. Heart J.,
July 1, 2011;
32(13):
1605 - 1613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Drazin, A. Choulakian, M. Nuno, P. Kornbluth, and M. J. Alexander
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting
JNIS,
June 1, 2011;
3(2):
177 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. S. Tantry, D. J. Kereiakes, and P. A. Gurbel
Clopidogrel and Proton Pump Inhibitors: Influence of Pharmacological Interactions on Clinical Outcomes and Mechanistic Explanations
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
365 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Bates, W. C. Lau, and D. J. Angiolillo
Clopidogrel-Drug Interactions
J. Am. Coll. Cardiol.,
March 15, 2011;
57(11):
1251 - 1263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Park, J. J. Park, K.-H. Jeon, S.-H. Kang, I.-Y. Oh, H.-M. Yang, H.-J. Cho, H.-Y. Lee, H.-J. Kang, B.-K. Koo, et al.
Enhanced Clopidogrel Responsiveness in Smokers: Smokers' Paradox Is Dependent on Cytochrome P450 CYP1A2 Status
Arterioscler Thromb Vasc Biol,
March 1, 2011;
31(3):
665 - 671.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tran, J. Tafreshi, and R. G. Pai
Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians
Journal of Cardiovascular Pharmacology and Therapeutics,
December 1, 2010;
15(4):
326 - 337.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. A. Gurbel, U. S. Tantry, and A. R. Shuldiner
Letter by Gurbel et al Regarding Article, "Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement"
Circulation,
October 5, 2010;
122(14):
e478 - e478.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sibbing, W. Koch, D. Gebhard, S. Braun, J. Stegherr, T. Morath, A. Schomig, N. von Beckerath, A. Kastrati, and T. Schuster
Response to Letter Regarding Article, "Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement"
Circulation,
October 5, 2010;
122(14):
e479 - e479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Fletcher and K. K. Thalinger
Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention
Crit. Care Nurse,
October 1, 2010;
30(5):
45 - 54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bonello, U. S. Tantry, R. Marcucci, R. Blindt, D. J. Angiolillo, R. Becker, D. L. Bhatt, M. Cattaneo, J. P. Collet, T. Cuisset, et al.
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
J. Am. Coll. Cardiol.,
September 14, 2010;
56(12):
919 - 933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bellemain-Appaix, G. Montalescot, J. Silvain, O. Barthelemy, F. Beygui, J.-P. Collet, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, et al.
Slow Response to Clopidogrel Predicts Low Response
J. Am. Coll. Cardiol.,
February 23, 2010;
55(8):
815 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Gurbel and U. S. Tantry
Combination Antithrombotic Therapies
Circulation,
February 2, 2010;
121(4):
569 - 583.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Berger, D. L. Bhatt, S. R. Steinhubl, M. Shao, P. G. Steg, G. Montalescot, W. Hacke, K. A. Fox, A. M. Lincoff, E. J. Topol, et al.
Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease
Circulation,
December 8, 2009;
120(23):
2337 - 2344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hagihara, M. Kazui, A. Kurihara, M. Yoshiike, K. Honda, O. Okazaki, N. A. Farid, and T. Ikeda
A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
Drug Metab. Dispos.,
November 1, 2009;
37(11):
2145 - 2152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rudez, H. J. Bouman, J. W. van Werkum, F. W.G. Leebeek, A. Kruit, H. J.T. Ruven, J. M. ten Berg, M. P.M. de Maat, and C. M. Hackeng
Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions
Circ Cardiovasc Genet,
October 1, 2009;
2(5):
515 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet and G. Montalescot
Review: Platelet Function Testing and Implications for Clinical Practice
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
157 - 169.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Perez de Prado, C. Cuellas, A. Diego, A. de Miguel, and F. Fernandez-Vazquez
Platelet Reactivity and Stent Thrombosis: Still Some Issues to Solve
J. Am. Coll. Cardiol.,
August 11, 2009;
54(7):
666 - 667.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sibbing, N. von Beckerath, and A. Kastrati
Reply
J. Am. Coll. Cardiol.,
August 11, 2009;
54(7):
667 - 668.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines
Combining Antiplatelet and Anticoagulant Therapies
J. Am. Coll. Cardiol.,
July 7, 2009;
54(2):
95 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation,
May 19, 2009;
119(19):
2625 - 2632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon, and M. S. Sabatine
Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1273 - 1278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Smoking Enhances Platelet Inhibition by Clopidogrel
Journal Watch Cardiology,
September 10, 2008;
2008(910):
3 - 3.
[Full Text]
|
|
|
|
